These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10769990)

  • 21. [Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro].
    Ino Y; Suzuki K; Sato T; Iwaki M
    Nihon Yakurigaku Zasshi; 1986 Dec; 88(6):449-55. PubMed ID: 2435641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of synthetic protease inhibitor on the sphincter of Oddi function in dogs].
    Matsumura T; Yada S; Miyoshi Y; Komi N
    Nihon Shokakibyo Gakkai Zasshi; 1991 Oct; 88(10):2663-70. PubMed ID: 1758083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved left ventricular unloading and circulatory support with synchronized pulsatile left ventricular assistance compared with continuous-flow left ventricular assistance in an acute porcine left ventricular failure model.
    Letsou GV; Pate TD; Gohean JR; Kurusz M; Longoria RG; Kaiser L; Smalling RW
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):1181-8. PubMed ID: 20546799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic antiproteases in acute pancreatitis: an experimental study.
    Dobosz M; Sledziński Z; Babicki A; Juszkiewicz P; Basiński A; Wajda Z
    Mt Sinai J Med; 1992 Jan; 59(1):43-6. PubMed ID: 1734237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.
    Han X; Wang N; Li J; Wang Y; Wang R; Chang J
    Chem Biol Interact; 2019 Jan; 297():80-84. PubMed ID: 30393114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M; Tanaka K; Hiraiwa T; Tanaka K
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
    Furukawa K; Iida T; Shiba H; Fujiwara Y; Uwagawa T; Shimada Y; Misawa T; Ohashi T; Yanaga K
    Oncol Rep; 2010 Oct; 24(4):843-50. PubMed ID: 20811662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nafamostat mesilate prevents warm ischemia-reperfusion injury in canine pancreas autotransplantation.
    Shimizu Y; Nakai I; Morita S; Uchiyama K; Yoshimura T; Itokawa Y; Oka T
    Transplant Proc; 1995 Dec; 27(6):3191-2. PubMed ID: 8539906
    [No Abstract]   [Full Text] [Related]  

  • 29. Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.
    Hiramatsu Y; Homma S; Sato Y; Sato S; Matsuzaki K; Shigeta O; Sakakibara Y
    Ann Thorac Surg; 2005 Apr; 79(4):1326-32. PubMed ID: 15797071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
    Shimada M; Matsumata T; Shirabe K; Kamakura T; Taketomi A; Sugimachi K
    J Am Coll Surg; 1994 May; 178(5):498-502. PubMed ID: 8167888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
    Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
    Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.
    Yamashita Y; Ishiguro Y; Sano D; Kimura M; Fujita K; Yoshida T; Horiuchi C; Taguchi T; Matsuda H; Mikami Y; Tsukuda M
    Auris Nasus Larynx; 2007 Dec; 34(4):487-91. PubMed ID: 17337140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors.
    Takeyama M; Ishida T; Kokubu N; Komada F; Iwakawa S; Okumura K; Hori R
    Pharm Res; 1991 Jan; 8(1):60-4. PubMed ID: 1901649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model.
    Adachi YU; Obata Y; Suzuki K; Katoh H; Itagaki T; Doi M; Sato S
    J Anesth; 2009; 23(4):624-7. PubMed ID: 19921382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
    Kimura T; Fuchimoto S; Iwagaki H; Hizuta A; Orita K
    J Int Med Res; 1992 Aug; 20(4):343-52. PubMed ID: 1511773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
    Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
    Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device.
    Han J; Takeda K; Takayama H; Kurlansky PA; Mauro CM; Colombo PC; Yuzefpolskaya M; Fukuhara S; Truby LK; Topkara VK; Garan AR; Mancini DM; Naka Y
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):520-7.e1. PubMed ID: 26806510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011.
    Holman WL; Naftel DC; Eckert CE; Kormos RL; Goldstein DJ; Kirklin JK
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):437-41.e1. PubMed ID: 23490245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis.
    Keck T; Balcom JH; Antoniu BA; Lewandrowski K; Warshaw AL; Fernández-del Castillo CF
    Surgery; 2001 Aug; 130(2):175-81. PubMed ID: 11490346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.